Inactive Instrument

All News NuGenerex Immuno-Oncology, Inc.

Equities

NUGX

US67053X1028

All News

Unlock all the news: Be the first to know and act before the market!

NUGENEREX IMMUNO-ONCOLOGY, INC. : Changes in Control or Registrant, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	10/04/23	AQ
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	23/07/21	AQ
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/06/21	AQ
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021	14/06/21	CI
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.	19/05/21	CI
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	27/04/21	AQ
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission	12/04/21	CI
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	12/03/21	AQ
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021	12/03/21	CI
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	17/12/20	CI
NuGenerex to Seek Merger or Acquisition Opportunities	15/12/20	CI
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	25/11/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	23/11/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	09/10/20	CI
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets	07/10/20	CI
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	06/10/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	24/09/20	CI
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.	14/09/20	CI
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)	17/08/20	CI
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility	15/07/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News NuGenerex Immuno-Oncology, Inc.

Equities

NUGX

US67053X1028

All News

Filters